MeSH tree: E05.318.372
The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D ...
Apr 20, 2026
0
5
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according ...
Apr 20, 2026
0
6
The U.S. Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies.
Apr 17, 2026
0
5
Acetaminophen, which also goes by names like paracetamol or Tylenol, is a common over-the-counter pain reliever and fever reducer. It is often prescribed during pregnancy to help with mild to moderate pain. Recently, there ...
A large international study has found that asundexian, an investigational anti-clotting medication, reduces the risk of a stroke in people who recently experienced a stroke or transient ischemic attack (TIA) caused by a clot ...
Apr 15, 2026
0
80
Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live ...
Apr 14, 2026
0
31
A clinical trial led by University of Auckland researchers found that high-intensity therapy for patients begun within two weeks of a stroke did not improve hand and arm recovery beyond standard care. Targeting new treatments ...
Mar 26, 2026
0
2
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and can cause various types of cancer. Prophylactic HPV vaccination is highly effective and has been recommended in Switzerland since ...
Mar 25, 2026
0
4
An experimental vaccine for Lyme disease is broadly effective, pharmaceutical companies Pfizer and Valneva announced Monday; however, the latter firm's shares fell because the clinical trial did not reach its main goal.
Mar 23, 2026
0
8
Findings from two early clinical studies suggest a new dual-action antimalarial drug candidate is well tolerated in humans. The first-in-class clinical candidate, MK7602, is being developed by WEHI and global biopharmaceutical ...
Mar 19, 2026
0
20
